SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?


To: SEC-ond-chance who wrote (83871)4/24/2003 3:47:10 PM
From: StockDung  Respond to of 122087
 
SEEKING VICTIMS AND INFORMATION ON SURGILIGHT INC AND CONOLOG AND OTHER ASSOCIATED STOCKS

OTC Financial Network - Management Team

Geoffrey J. Eiten, RIA - President & Founder
After pinpointing a long-standing industry void, Mr. Eiten founded OTC Financial Network as the only full-service investor relations firm specifically dedicated to the representation of micro- and small-cap, emerging growth companies. A seasoned investment professional of over 25 years and a registered investment advisor since 1979, Mr. Eiten is renowned throughout the investment community. For information detailing Mr. Eiten's illustrious career, please see "About Our Founder."

---------------------------------------------------------------------------------------
Geoff Eiten recommends Surgilight Inc and is also IR
----------------------------------------------------------------------------------------

Wednesday March 22, 8:28 am Eastern Time
Company Press Release
OTC Financial Network Announces Investment Opinion On SurgiLight Inc. OTC Financial Network Issues Research Report On SurgiLight Inc.
ORLANDO, Fla.-March 22, 2000- SurgiLight Inc. (OTCBB:SRGL)announced today that
OTC Financial Network, a division of National Financial Communications
Corporation (NFC) of Needham, Massachusetts, has issued an in-depth
analytic report on the Company. The report is available online, at
www.otcfn.com/srgl/4page.html. The report is also available for reprint by
calling 781/444-6100, ext.11. Geoffrey J. Eiten, president of National Financial
Communications, commented, ``The market for laser applications in the
ophthalmology and dermatology industries is enormous, and SurgiLight, Inc. has
the innovative technology to assume a position of leadership.''
SurgiLight is a world leader in the development of new infrared technologies,
and a pioneer and inventor of scanning lasers and laser presbyopia reversal. The
Company continues to receive royalty income from international eye laser and
cosmetic centers. The presbyopia potential market is over $150 billion in US and
$1.4 trillion worldwide, according to SurgiLight's market analysis.
OTC Financial Network, a division of National Financial Communications Corp., is
a financial communications and investor relations firm specializing in the
representation of micro-cap companies.
Forward-looking statements in this release are made pursuant to the ``safe
harbor'' provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
OTC Financial Network, a division of National Financial Communications
Corporation, serves as a special advisor to the featured Company and has
received fees for services. This is not an offer to buy or sell securities.
Information or opinions in this report are presented solely for informative
purposes, and are not intended nor should they be construed as investment
advice. Contact: SurgiLight Inc. OTC Financial Network
J.T. Lin Geoffrey Eiten
407-482-4555 781-444-6100 x.13
Surgilight@aol.com geiten@otcfn.com
surgilight.com

--------------------------------------------------------------------------

Surgilight turns out to be massive fraud

-----------

Securities and Exchange Commission
Washington, D.C.
Litigation Release No. 17469 / April 11, 2002
Securities and Exchange Commission v. Surgilight, Inc., Jui-Teng Lin, Yuchin Lin and Aaron Tsai, Civil Action No. 6:02-CV-431-0RL-18KRS (G. Kendall Sharp, J.; Karla R. Spaulding, M.J.) (M.D. Fla. filed April 11, 2002)
SEC Sues Laser Eye Surgery Company, Two Securities Law Recidivists and Others In Multi-Million Dollar Stock Manipulation
The Securities and Exchange Commission ("Commission") today filed a civil action against a laser eye surgery company, two securities law recidivists, and a shell company broker in a multi-million dollar stock manipulation involving Surgilight, Inc., a publicly traded company headquartered in Orlando, Florida. One defendant, Dr. Jui-Teng Lin, was also indicted today by the United States Attorney's Office for the Eastern District of New York on related criminal charges. The Commission's complaint, filed in the United States District Court for the Middle District of Florida, alleges that Dr. Lin and his wife, Yuchin Lin, reaped over $1,700,000 in ill-gotten gains from manipulating the common stock of Surgilight. According to the complaint, the Lins artificially inflated the market price of Surgilight stock tenfold (from approximately $2.50 to over $25 per share) through a series of false and misleading press releases issued by Surgilight. The press releases detailed the company's purported ability to cure age-induced vision deterioration known as "Presbyopia." The Lins simultaneously dumped a substantial amount of Surgilight stock on an unsuspecting public through two nominee accounts and moved the proceeds through a series of offshore accounts to a domestic bank account held in Surgilight's name that they controlled. The Lins settled a prior civil action brought by the Commission involving another laser eye surgery company in September 1998 [see SEC v. Jui-Teng Lin and Yuchin Lin, Litigation Release No. 15870 (Sept. 3, 1998)].The Commission further alleges that the Lins were assisted by Aaron Tsai of Henderson, Kentucky. According to the complaint, Tsai sold the Lins the publicly traded shell that became Surgilight, supplied the stock that was dumped out of the nominee accounts and, after Surgilight became a publicly-held entity, remained with the company as a consultant. At the height of the manipulation, Tsai sold over $1,000,000 worth of Surgilight stock for his own account. The Commission charges Dr. Lin with violations of Sections 5(a), 5(c), and 17(a) of the Securities Act of 1933 ("Securities Act") and Sections 10(b), 13(d), and 16(a) of the Securities Exchange Act of 1934 ("Exchange Act") and Rules 10b-5, 13d-1, 13d-2, 16a-2, and 16a-3 thereunder. Ms. Lin and Surgilight are charged with violations of Sections 5(a), 5(c), and 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. Tsai is charged with violations of Sections 5(a) and 5(c) of the Securities Act and aiding and abetting Dr. Lin and Ms. Lin's violations of Section 10(b) of the Exchange Act and Rules 10b-5 thereunder. The Commission seeks permanent injunctions, disgorgement of ill-gotten gains with prejudgment interest, and civil penalties from all defendants and an officer and director bar against Dr. Lin.The Commission acknowledges assistance provided by NASD Regulation Inc. and the United States Attorney's Office for the Eastern District of New York in this matter.For tips on how to avoid Internet "pump-and-dump" stock manipulation schemes, visit sec.gov. For more information about Internet fraud, visit sec.gov. To report suspicious activity involving possible Internet fraud, visit sec.gov Complaint in this matter.

------------------------------------------------------------------------------------------------

SEXI Dr. Kenneth D. Steiner rounds out Geoff Eiten's current management team

otcfn.com nfnonline.com National Financial Network - Management Team nfnonline.com
======================================
Management Team google.com.

Dr. Kenneth D. Steiner, MD, RIA - Special Medical Consultant Having embarked upon his medical career as a clinical fellow at the Harvard Medical School in 1979, Dr. Steiner emerged a specialist in emergency medicine and assistant professor of Ambulatory Care. After establishing a private practice in 1983, he became a registered investment advisor and medical review officer, and has served as medical consultant to numerous Fortune 500 companies. Today Dr. Steiner maintains a private practice and is a fellow of the American Academy of Emergency Medicine. At NFN, he serves as a consultant for clients in the biotech, medical, healthcare, and biomedical fields. Dr. Steiner utilizes his vast experience and personal contacts within the financial and medical fields to increase awareness of the opportunities offered within the small-cap arena.
-------------------------

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. LITIGATION RELEASE NO. 16695 / September 11, 2000 SECURITIES AND EXCHANGE COMMISSION v. KENNETH STEINER AND WOODBRIDGE FAMILY MEDICAL ASSOCIATES, P.C., Civil Action No. 00-02145 (D.D.C.) NEW JERSEY DOCTOR AND HIS MEDICAL PRACTICE PAY $1.3 MILLION TO SETTLE SEC CHARGES OF SELLING UNREGISTERED SYSTEMS OF EXCELLENCE SECURITIES The Securities and Exchange Commission today announced that on September 8, 2000 the Honorable Gladys Kessler of the United States District Court for the District of Columbia entered final judgments against Kenneth Steiner ("Steiner"), a New Jersey physician, and his medical practice, Woodbridge Family Medical Associates, P.C. ("Woodbridge"), requiring them to collectively pay over $1.3 million in disgorgement, prejudgment interest and civil penalties. The Commission's complaint, filed on September 7, 2000, alleges that in two separate transactions in March and June 1996, Steiner acquired -- for himself, his corporate medical practice and in the names of family nominees -- a total of 689,655 shares of newly-issued Systems of Excellence, Inc. ("SOE") stock in a private placement at a total cost of $200,000. The shares that Steiner and Woodbridge acquired were neither registered nor exempt from registration but were nevertheless conveyed to them without the required restrictive legend as part of a scheme orchestrated by Charles Huttoe, former president of SOE, to manipulate the market for SOE securities. According to the complaint, Steiner and Woodbridge soon resold nearly all of these newly-issued and unregistered shares into the manipulated market, realizing net profits of $924,789. Simultaneously with the filing of the Complaint, Steiner and Woodbridge, without admitting or denying the SEC's allegations, settled the action by consenting to entry of the court's Order that: (i) permanently enjoins them from violating Sections 5(a) and (c) of the Securities Act of 1933; (ii) requires Steiner to disgorge his illegal profits of $602,648, plus prejudgment interest of $220,433; (iii) requires Woodbridge and Steiner to jointly and severally disgorge $322,141, plus prejudgment interest of $111,376; and (iv) requires Steiner to pay a civil penalty of $50,000. With the filing of this Complaint, and the subsequent payment by Steiner and Woodbridge, the Commission will have collected approximately $12 million in disgorgement, which will later be distributed by the Court-appointed receiver to victims of the SOE fraud. The Commission previously has made several announcements concerning these matters. See Lit Rel. 16632a (July 21, 2000), Securities Exchange Act Rel. 42616 (April 4, 2000), Lit Rel. 16343 (October 27, 1999), Lit. Rel. 15996 (December 9, 1998); Lit. Rel. 15906 (September 24, 1998); Lit. Rel. 15888 (September 18, 1998); Lit. Rel. 15617 (January 14, 1998); Lit. Rel. 15600 (December 22, 1997); Lit. Rel. 15571 (November 25, 1997); Lit. Rel. 15490 (September 12, 1997); Lit. Rel. 15286 (March 12, 1997); Lit. Rel. 15237 (January 31, 1997); Lit. Rel. 15185 (December 12, 1996); Lit. Rel. 15153 (November 7, 1996); Securities Exchange Act Rel. No. 33791 (October 7, 1996). The Commission's investigation in this matter is continuing. This enforcement action is part of the Commission's four-pronged approach to attacking Microcap abuses: enforcement, inspections, investor education and regulation. For information about the SEC's response to Microcap fraud, visit the SEC's Microcap Fraud Information Center at sec.gov. sec.gov
--------------------------------------------------------------------------

Geoffery J. Eiten tied to known stock manipulator MARIO IACOVIELLO who was associated with Notorious Boiler Room La Jolla Securities Corp. I am happy to add important investor information to Mario's resume.

National Financial Network - Management Team Geoffrey J. Eiten, RIA - President & Founder
John J. McElligott - Chief Operating Officer
Denelle Swaim - Chief Administrative Officer
Mario Iacoviello - Independent Affiliate/Western Region

nfnonline.com Mr. Iacoviello gained extensive experience in the financial industry through a decade of work in senior management positions with prestigious companies such as Baron Chase Securities, Oppenheimer, and Rodman & Renshaw. Through his work with these firms, Mr. Iacoviello has gained expertise in a variety of areas, including financing and the development of integral marketing strategies resulting in increased profitability. He has seamlessly adapted these skills for utilization in the arena of investor relations. NFN's clients and their investor base benefit from his broad financial background.
=====================================

CIVIL ACTION AGAINST MARIO IACOVIELLO The Commission announced the filing on September 7 of a final
judgment on consent against Mario J. Iacoviello of Vista, California
in the United States District Court for the Southern District of New
York. According to the Commission's complaint, filed on May 14,
1998, Iacoviello violated the antifraud provisions of the federal
securities laws while employed as a registered representative with
the San Diego branch office of La Jolla Securities Corp. by
accepting undisclosed compensation for recommending and selling
stock in RMS Titanic, Inc. to his clients. Without admitting or denying the allegations in the Commission's
complaint, Iacoviello consented to a permanent injunction against
future violations of Section 17(a) of the Securities Act of 1933 and
Section 10(b) of the Securities Exchange Act of 1934, and Rule 10b-5
thereunder. Iacoviello also consented to pay disgorgement of
$30,325 plus prejudgment interest thereon of $16,155.30, subject to
a waiver of all but $10,000 based upon Iacoviello's demonstrated
inability to pay. [SEC v. Paul V. Montle, LS Capital Corporation,
Paul V. Culotta, Carol C. Martino, CMA Noel, Ltd., Mario J.
Iacoviello, Ilan Arbel and Europe American Capital Corporation,
USDC, SDNY, 98 Civ. 3446, MP] (LR-16277)
======================================

SEC says former LS Capital officer Montle fined WASHINGTON, July 13 (Reuters) - Paul Montle, former president and chief executive of LS Capital Corp., was ordered to pay more than $415,000 and barred from serving as an officer or director for five years for alleged fraud involving three other companies in the early 1990s, regulators said on Friday. Montle, 53, who resides in Massachusetts, was also barred from participating in the sale of securities for five years, according to the Securities and Exchange Commission. The ruling, which was handed down on Thursday by a U.S. federal judge in New York, fines Montle $50,000, orders him to pay back more than $365,000 in disgorgement and interest, and bars him from holding executive roles in publicly-traded companies, closes an SEC civil case filed back in May 1998. Montle, while a CEO and director of Viral Testing Systems Corp., which marketed an HIV diagnostic test called "Fluorognost," more than doubled revenues and overstated revenue projections in two trade publications in 1992 and in a 1993 company press release, the SEC alleged. As chairman and CEO of gambling casino operator Lone Star Casino Corp., he intentionally left out in SEC filings the sale of more than 1 million shares to foreign investors in 1993 and altered minutes from board meetings and the company's financial books to cover it up, the SEC alleged. He was also accused of profiting more than $187,000 by manipulating in 1993 the stock of RMS Titanic Inc. , which owns the salvage rights to the sunken Titanic. Montle's "violations involving fraud and deceit were numerous and ongoing," and his "actions were knowing departures from the securities laws," the SEC quoted federal district judge Milton Pollack as saying. The ruling was made after a four-day trial in May, the SEC said. His attorney did not immediately return a telephone call seeking comment. 18:44 07-13-01

-------------------------------------------------------------------------------
click on this url CNLG and it will bring you to the conolog thread. Conolog is backed by notorious securities recivist Warren Schreiber

Subject 33191

-----------------------------------------

Case Study 2: Conolog Corp. The Company:
Conolog Corporation (NASDAQ: CNLG) The Challenge:
In January 2000, Conolog was almost a half-year into a corporate turn-around. Although the Company was moving towards profitability and was closing on significant contracts, its stock was not experiencing any volume, and it was consistently closing at less than a dollar. Conolog President Robert Benou knew he stood on the verge of being delisted from the NASDAQ. He - and Conolog - needed help in generating volume in the stock, and breaking the price ceiling that had been established. They turned to NFC. The Strategy:
Conolog and Benou were, on an almost daily basis, creating newsworthy opportunities that proved the Company was viable and worthy of investor interest. We decided to mount an aggressive press release campaign in tandem with a one-on-one phone campaign to our network of brokers - a full court press. Implementation:
On February 1, 2000, we started our press release campaign with an announcement that Conolog had retained our services. We immediately issued a second release, and the press was on. Virtually every other day through the month of February, we issued a press release about Conolog - its new products, its new contracts, its quarterly results - every piece of good news we could find to talk about. Each release was followed by a targeted email and fax blast to existing shareholders, our broker network, and potential investors following Conolog's industry. In conjunction with the release blitz, our telemarketing department followed up each and every release with a barrage of phone calls - to a highly targeted, and increasingly receptive audience. The Results:
In the first week of our campaign, Conolog's share value rose 225%. Volume rose to over 15 million shares in one day, and share value skyrocketed to a record high of $7.50.The Company's standing on the NASDAQ was preserved. In March, April and June, we sent Conolog on the road, both here in the United States and throughout Europe. The Company generated tremendous interest in the investment community, attracting the attention of a whole new crop of retail and institutional investors and resulting in significant financing opportunities. Today, Conolog has broadened its product and services capabilities through a series of highly targeted, successful acquisitions. It continues to generate innovative products, lucrative contracts, synergistic partnerships and strong investor interest. IR Services | Case Study 1 | Case Study 2 | Case Study 3 | Case Study 4 National Financial Network
300 Chestnut Street, Suite 200 Needham, MA 02492
800-870-0639 / 781-444-6100, fax- 781-444-6101 or email us
Copyright ©2000-2001 - National Financial Network
Best viewed with: Netscape, Microsoft IE, AOLDisclaimer

------------------------

FOR MORE INFORMATION ON con-o-log PLEASE VISIT Subject 33191

---------------------------

TheTruthseeker Report CON-o-log (CNLG, CNLGW) A warning to our Mom and Pop Investors
Conolog (CNLG, CNLGW)
5 Columbia Road Sommerville, NJ 08876 (908)-722-8081

While looking at the most active after-hours traders in early March, The Truthseeker came across this name, Conolog, which may merit further attention.

Conolog is a tiny company, taken public in 1995 by a tiny firm called IA

Rabinowitz & Co. (See Exhibit 1), which designs and distributes small electronic and electromagnetic components. The company has a history of uneven
sales and earnings (See Exhibit 2).

CNLG stock has done nothing for ages (See Exhibit 3), until suddenly, a barrage of press releases appeared over the past 6 weeks (See Exhibit 4). In this time
the stock has moved from under $1, to a current after-hours price of $8.

This flurry began with an announcement that EPS for the period ending Jan 31 00 would be 4 cents. There was, of course, the obligatory announcement about the
hot area of the moment, fiber optics. However, their "fiber optic" announcement was simply that you could attach a fiber optic connector (a type of plug sold by
countless firms, including Corning, HP, Siemens, AMP, etc) to some of their products.

Today's financials (See Exhibit 5) are very interesting. Here is a company with revenues of 1.5 million for the Q, but inventories of 3.2 million.

They announced earnings of 328k, but 2/3 of that was from taking credit for their prior losses under NJ state tax laws, actual earnings from the business would be 119k, or .02 per share, not the .06 reported, and LESS than the
.04 that they pre announced a few days ago!

Company's largest shareholder is an entity called CLOG LLC (See Exhibit 6), CLOG LLC is actually an individual named Warren Schreiber. Another holder is an entity called "Nybor". Nybor is listed as a consultant to CNLG, and
receives fee income from the company. Nybor is registered to the same address as Warren Schreiber. An SEC Schedule 13 (See Exhibit 7) indicates that Nybor and CLOG are
both, in fact, Warren Schreiber, and that the company has extended the life of an option it granted to CLOG LLC to purchase convertible debt of the company.

According to an older Schedule 13 (See Exhibit 8) the option is to purchase $2 million in debt, convertible to stock at $1 per share, creating an additional 2
million shares of CNLG, which would be a 37% dilution to current shareholders! This Schedule 13 also provides some details on the NASD's actions against Schreiber.

So, just who is Warren Schreiber? Schreiber is an associate of Randolph Pace. Basically, Schreiber is an ex-broker from VTR Capital, who is believed to have secretly controlled chop-stock house Sterling Foster. A Bloomberg News article
from September 1999 describes Schreiber's activities. (See Exhibit 9)

LOOK AT THIS....WARREN SCHREIBER DUMPED LOTS OF CNLG STOCK DURING THE PUMP

--------------------
SCHREIBER WARREN,10% BEN. OWNER,SELLS 895,000 FROM 02/01/00-02/1
3/16/0 2:49 (New York)

FORM 4

SEC - FROM 02/01/00-02/14/00, SCHREIBER WARREN, A BENEFICIAL OWNER
OF MORE THAN 10% OF SECURITY CLASS OF CONOLOG CORP
(TICKER:CNLG) SOLD 895,000 SHARES AT $1.38 - $6.38, BRINGING
HOLDINGS TO 300,000 SHARES.

The Washington Service reports only purchases and sales (both open
market and private) of common stock.

Additional insider trading information is available to qualified
professional investors through our web site (www.washserv.com).
Further information on our services may be obtained by calling
202-778-1380, e-mailing us at info@washserv.com, or by typing WSA<GO>.

Buyer Beware!!



To: SEC-ond-chance who wrote (83871)4/24/2003 3:49:19 PM
From: StockDung  Respond to of 122087
 
OTC Financial Network Announces Investment Opinion On SurgiLight Inc. OTC Financial Network Issues Research Report On SurgiLight Inc.

ORLANDO, Fla.-March 22, 2000- SurgiLight Inc. (OTCBB:SRGL)announced today that
OTC Financial Network, a division of National Financial Communications
Corporation (NFC) of Needham, Massachusetts, has issued an in-depth
analytic report on the Company. The report is available online, at
otcfn.com . The report is also available for reprint by
calling 781/444-6100, ext.11. Geoffrey J. Eiten, president of National Financial
Communications, commented, ``The market for laser applications in the
ophthalmology and dermatology industries is enormous, and SurgiLight, Inc. has
the innovative technology to assume a position of leadership.''
SurgiLight is a world leader in the development of new infrared technologies,
and a pioneer and inventor of scanning lasers and laser presbyopia reversal. The
Company continues to receive royalty income from international eye laser and
cosmetic centers. The presbyopia potential market is over $150 billion in US and
$1.4 trillion worldwide, according to SurgiLight's market analysis.
OTC Financial Network, a division of National Financial Communications Corp., is
a financial communications and investor relations firm specializing in the
representation of micro-cap companies.
Forward-looking statements in this release are made pursuant to the ``safe
harbor'' provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.
OTC Financial Network, a division of National Financial Communications
Corporation, serves as a special advisor to the featured Company and has
received fees for services. This is not an offer to buy or sell securities.
Information or opinions in this report are presented solely for informative
purposes, and are not intended nor should they be construed as investment
advice. Contact: SurgiLight Inc. OTC Financial Network
J.T. Lin Geoffrey Eiten
407-482-4555 781-444-6100 x.13
Surgilight@aol.com geiten@otcfn.com
surgilight.com

--------------------------------------------------------------------------



To: SEC-ond-chance who wrote (83871)4/24/2003 3:53:20 PM
From: StockDung  Respond to of 122087
 
SURGILIGHT FRAUD REPORT web.archive.org

AN INSIGHTFUL INVESTMENT (back to top)
By Geoffrey J. Eiten, Publisher

The market for laser applications in the ophthalmology and dermatology industries is enormous, and SurgiLight, Inc. has the innovative technology to assume a position of leadership.

The Company’s research and development of infrared laser technology has paid off in three patents pending on devices used in vision correction, microsurgery and LASIK (Laser in-situ Keratomileusis), and the treatment of presbyopia (age-induced farsightedness).

Currently, the Company is in full commercialization of these devices, as well as a UV (ultraviolet) device designed for the treatment of psoriasis and vitiligo. SurgiLight has shrewdly freed itself from the need to pay royalties to competitors; with its move to infrared technology it has created a body of treatment around its own proprietary technology which it can, in turn, license to others.

This is, indeed, the premise behind its marketing of the devices here in the United States. While the Company will continue to sell the devices to individual physicians internationally, within this country it will make them available as integral parts of its chain of Laser Eye Centers.

The Company also reaps revenue benefits from usage royalties paid by hospitals and medical centers. Revenues from replacement of component parts will provide long-term income.

As the Company leverages its technology and marketing strategies to realize its twin goals of marketshare and expansion, shareholders should continue to see strong gains in revenues and profits in the foreseeable future.

--------------------------------------------------------------------------------

CORPORATE PROFILE (back to top)
In January, 2000, SurgiLight spun off its Cosmetic Mobile Laser Centers and Thermal Infrared Technology division, to focus completely on developing technology for the fast growing industry of providing lasers for the ophthalmology and dermatology markets.

Currently, the Company has patents pending on three new infrared laser devices:

Model IR-3000, an infrared laser for treatment of presbyopia and use in microsurgery

Model IR-3001, an infrared laser for vision correction, and

Model LPD-100, a third device for presbyopia currently being tested in Venezuela.

A decade of research and development by the Company’s key personnel has resulted in its position as a world-leader in groundbreaking technology, including:

the first Infrared Laser (IR) for LASIK,

the first system for Presbyopia correction, and

the first UV-laser for treatment of psoriasis and vitiligo.

SurgiLight is also the only company that has the in-house UV and IR technology expertise to support its 18 operating Laser Eye Centers.

Since acquiring the Laser Center chain twelve months ago, SurgiLight reports a threefold increase in the number of procedures performed, from 40 to 120 eyes.

Although the Company will market its infrared lasers to individual ophthalmologists in the international market, it will license the devices through an expanding number of Laser Centers here in the United States.

SurgiLight believes that its infrared laser devices hold benefits for patients as well as for medical professionals.

Infrared lasers are ‘cold’ lasers; that is, they generate less heat and do not invade the eye the way UV, or ‘thermal’ lasers do. As a result, there is more efficient healing, less regression, and fewer mutagenic effects after infrared procedures.

The Company hopes to penetrate the ophthalmologic market by focusing on 1-2% of individuals aged 44-60, almost 100% of which can be expected to develop presbyopia, or age-incurred farsightedness. That market alone translates into approximately $3 billion dollars in revenues from procedures.

In dermatology, the Company hopes to realize 10-15% marketshare of the potential $120 million psoriasis and vitiligo treatment revenues.

--------------------------------------------------------------------------------

STOCK INFORMATION (back to top)

Business: Infrared LaserTechnology for Ophthalmology and Dermatology
AMEX Symbol: SRGL
Click here for updated stock information
Common Shares Outstanding: 21.38 million
Estimated Public Float: 2.2 million
Insider Ownership: 75%
Fiscal Year End: December
Employees: 17
Market Makers: 8
Company Contacts: Investor Relations:
Surgilight, Inc. OTC Financial Network
12001 Science Drive 1040 Great Plain Ave.
Suite 140 2nd Floor
Orlando, FL 32826 Needham, MA 02492
(407) 482-4555 781-444-6100 ext. 13
Surgilight@aol.com geiten@nfnonline.com

Dr. J.T. Lin Geoffrey J. Eiten
800-640-2656 ext. 13
Chairman & President President

Questions? Contact OTC Financial Network at 800-878-9460/781-444-6100 ext. 13 or see web.archive.org and web.archive.org.

--------------------------------------------------------------------------------

FINANCIAL PROFILE & ANALYSIS (back to top)
9MtFY1999 9MtFY1998 % Change
Revenues $2,300,000 $734,000 221%
Net income (loss) $207,000 ($97,000) 313%
* Revenues and net income for the nine months ended September 30, 1999.

SurgiLight has devoted ten years to research and
development and is now in its commercialization phase.
The Company’s patented infrared laser technology eliminates the need to pay heavy patent and licensing fees for ultraviolet laser technology developed by IBM.

In the first nine months of 1999, the Company increased its revenues 221% over the same period in 1998. It increased net income a remarkable 313%, from a loss of $97,000 in the first nine months of 1998, to a gain of $207,000 in the same period in 1999.
The potential market for ophthalmologic applications is estimated at $150 billion in the U.S. alone, with dermatological applications estimated at over $120 million annually.

--------------------------------------------------------------------------------

MARKET OPPORTUNITIES (back to top)
With unique patented laser technology in place, SurgiLight is poised for a two-pronged approach to profits. The Company has developed ‘cold’ laser treatments for applications in both the ophthalmology and dermatology marketplaces.

‘Cold’ is the differential factor that distinguishes SurgiLight’s technology from existing leaders in the laser-correction industry. The Company’s products, the IR-3000 and the IR-3001, operate on an infrared technology base, rather than an ultraviolet base as do all its competitors for LASIK and presbyopia.

In addition to establishing Surgilight as an innovator of new laser technology, the development of non-thermal lasers frees the Company from the burden of paying patent and licensing fees to IBM, the owner of ultraviolet laser technology patents.

And the patient benefits as well. The IR-3001’s infrared beam generates far less heat than other conventional infrared lasers. The result: minimized thermal excitation, triggering only a few microns of tissue damage, as compared to the few hundred microns of thermal damage caused by other infrared lasers.

Within the ophthalmology industry, various applications exist for Surgilight’s technology. The potential market is staggering. For treatment of presbyopia alone, revenues are estimated at $150 billion in the U.S. and $1.5 trillion worldwide. Cataract correction and microsurgery constitute additional revenue streams, which will be augmented by royalty fees charged to the surgeons who perform the procedures.

Dermatologic laser applications represent yet another area of profit for SurgiLight, through treatment of the disorders psoriasis and vitiligo. Procedure revenues in this industry are estimated at over $120 million annually.

Through sales of its equipment and royalty fees, Surgilight projects a 1- 2% share of the ophthalmology market, and a 10-15% share in the dermatology treatment industry.

--------------------------------------------------------------------------------

PIONEERING TECHNOLOGY (back to top)
The following technologies have been pioneered through ten years of dedicated research and development:

1991-92: The world’s first solid-state UV Laser

1992-92: Design and invention of the Mini-Excimer Laser

1994: Design and invention of the Scanning Laser

1996-97: SmartScan for topo-linked LASIK System

1998-99: World’s first IR-laser for LASIK**

1998-99: World’s first device for Laser Presbyopia Reversal (LPR)**

1998-99: World’s first UV-laser for Psoriasis and Vitiligo treatments

** Patents Pending
--------------------------------------------------------------------------------

RECENT DEVELOPMENTS (back to top)
February 2000

Announces Submission of Application for NASDAQ Market Listing - The Company believes that it is fully qualified and fits all the criteria necessary for inclusion on the NASDAQ National Market.

January 2000

Obtains Exclusive Marketing License for New Waterjet Devices for Ophthalmic Applications. The devices, HydroKeratome and Pulsatome, are used for vision correction and cataract surgery. The Company believes that more than 100 waterjet devices may be sold within one year from FDA approval, and anticipates long term recurring income from the consumable parts associated with the devices.

Focuses on New Infrared IR Laser Technologies and Hires Key Industry Professional. The Board of Directors approves the spin off of two divisions not associated with the Company’s core technology, and hires a Senior Vice President and Chief Operating Officer, Timothy J. Shea. Shea is responsible for corporate operations, clinical research, FDA regulatory submissions, and assists the President in the daily operations of the Company. The spin-off allows the Company to focus on development of its two new infrared (IR) laser based systems for vision correction.

Board of Directors approves a 2 for 1 split of its common stock, in response to a growing market demand for those shares. After the split, the Company will have total outstanding shares of 21.6 million.

Submits a Clinical Trial Protocol to Mt. Sinai Hospital in New York for a new ophthalmologic procedure called Laser Presbyopia Reversal (LPR). The Company believes its new treatment offers advantages over non-laser methods including faster, more precise healing, with less regression and less mutagenic effects after surgery.

December 1999

Submits 510K Premarket Notification for UV Laser Phototherapy with Clinical Results from Mt. Sinai Hospital in New York. The UV-308 excimer laser treats skin disorders including psoriasis and vitiligo. SurgiLight is one of two companies treating psoriasis with UV lasers, and the only provider of UV laser treatment for vitiligo.

Company Announces Two New Technologies for Infrared Laser Vision Correction. The Model IR-3000 is designed for microsurgery and presbyopia procedures. The IR-3001 will be used for vision correction, including LASIK and presbyopia procedures.

Third Quarter 1999 Results Show Record Sales and Earnings. Results for the nine months ending September 30, 1999 showed an increase of approximately 220% in revenues over the same period in 1998.

November 1999

SurgiLight Mergers Complete. Company announces that it has completed mergers that include medical laser and infrared technologies, laser eye centers, and mobile cosmetic centers. SurgiLight is fully SEC reporting and traded on the OTC Bulletin Board. The Company is currently focusing on the development of new infrared (IR) lasers for vision correction.

--------------------------------------------------------------------------------

MANAGEMENT (back to top)
Dr. J.T. Lin, President and Chief Executive Officer, founded SurgiLight in 1998. He is the inventor of the scanning laser for vision correction (1994), and the solid-state UV-laser for PRK (1992). In 1991, Dr. Lin founded LaserSight, after four years as an Associate Professor at the University of Central Florida’s Laser Center. Throughout his twenty year career in laser developments, he has published over 80 professional papers and books in his field.

Dr. M.W. Hwang, Vice President of Research and Development, has pioneered topography-linked laser vision correction using the most advanced software for customized corneal reshaping. Dr. Hwang has a Ph.D. in Electrical Engineering and has more than 10 years experience in new laser development.

Timothy J. Shea, Senior Vice President and Chief Operating Officer, prior to joining SurgiLight, was President of the Medical Division at Laser Analytics, Inc. He has almost two decades of experience in the public and private medical laser and electro-optic industry, focusing on the design, development, commercialization and regulatory submissions of a variety of medical and scientific lasers and accessories.

Dr. Raymond Gailitis, Medical Director, is an internationally recognized ophthalmologist and member of several distinguished professional associations. He has more than 5 years’ experience in refractive surgery and has authored more than 16 publications, including the pioneer paper, with Drs. Lin and Waring in 1991, for a solid-state UV laser for vision correction.

--------------------------------------------------------------------------------

MARKET STRATEGIES (back to top)
In the first quarter of the fiscal year, SurgiLight has rededicated itself to the research and development of new, innovative ‘cold’, or infrared (IR) laser technology. Concurrently, the Company will continue the successful commercialization of existing devices and technology, and increase its lucrative Laser Eye Center holdings through nationwide expansion.

Of all the applications possible for lasers (both Ultraviolet and Infrared) in the medical marketplace, those related to ophthalmology and dermatology represent by far the largest opportunity for revenue.

SurgiLight is poised to take distinct advantage of this situation. The Company hopes to achieve a 1- 2% marketshare of the potential $150 billion (U.S.) revenues from ophthalmology procedures, such as microsurgery, treatment of presbyopia, and vision correction with its three new devices.

The fact that its devices do not rely on UV technology translates into freedom from licensing and patent fees to competitors like IBM and VISX. In addition, Infrared technology holds benefits for the patient -- more rapid healing and less mutagenic effects than UV lasers. Thus the Company’s devices can be marketed as advantageous to both the medical profession and its clients.

SurgiLight will continue to offer its devices on an individual basis to physicians outside the United States, but will market them as an integral part of Laser Eye Centers throughout the nation, thus insuring revenue generation through usage fees. Further long term revenues will be generated through replacement sales for various components of the devices.

--------------------------------------------------------------------------------

INVESTMENT HIGHLIGHTS (back to top)
Since its inception in 1998, SurgiLight has positioned itself as the developer and sole proprietor of Infrared (IR) Laser Technology for application in ophthalmology and dermatology,, and as the only provider of both the traditional UV and its newly developed IR laser technologies for vision correction and surgery.
Within one year - 1998 to 1999 - the Company moved from research and development into a full commercialization phase, turning its financial standing around completely with a 220% growth in revenue.
Because SurgiLight’s newest products are infrared based, the Company can avoid heavy licensing and patent fees for utilizing the UV and excimer technology owned by IBM and other competitors.
The market for the Company’s technology in presbyopia corrections has been estimated at $150 billion in the United States, with a worldwide market of $1.5 trillion. In addition to market share in those revenues, SurgiLight will incur long-term recurring revenues from procedure and/or royalty fees collected from users of their technology. The Company currently has contracts with 18 hospitals who are using its scanning lasers.

--------------------------------------------------------------------------------

LASER EYE CENTERS (back to top)


SurgiLight currently operates 18 Laser Eye Centers (LEC) worldwide, using the most advanced systems.

SurgiLight’s international LECs now offer the new Laser Presbyopia Reversal (LPR) procedure using the Company’s patent pending technologies. Clinical studies in the U.S. will begin in the near future.

The LEC at Ft. Lauderdale-Plantation is a state-of-the-art facility with over 25 certified MDs providing highest quality LASIK procedures.

In addition to the LEC procedure income, the Company is continuing to receive income from the cosmetic mobile laser centers.

--------------------------------------------------------------------------------

DISCLAIMER (back to top)
This is a publication of OTC Financial Network, a financial communications and investor relations company. OTC Financial Network, a division of National Financial Communications Corporation serves as special advisor to the featured Company and has received fees for services, including a fee of three thousand free trading shares for the writing, preparation and distribution of this report. This is not an offer to buy or sell securities. Information or opinions in this report are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. Companies mentioned herein may carry a high investment risk; readers should carefully review the companies thoroughly with their registered investment advisor or registered stockbroker. The analysis contained herein does not purport to be a complete study of the featured Company or other companies mentioned. Information used and statements of fact have been obtained from the featured Company and other sources, but not verified nor guaranteed by OTC Financial Network as to completeness or accuracy. Such information is subject to change without notice. Opinions stated herein may be solely OTC Financial Network's or the indicated sources, and not necessarily those of the featured Company. Officers, directors, and employees of OTC Financial Network and financial analysts mentioned, and members of their families may hold a position and may from time to time trade in these securities for their own accounts. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. © 2000 OTC Financial Network. All rights reserved. Duplication of this report without the expressed written permission of OTC Financial Network is strictly prohibited. To be placed on OTC Financial Network's mailing list, call: 781-444-6100 or see web.archive.org.



To: SEC-ond-chance who wrote (83871)4/24/2003 9:04:46 PM
From: StockDung  Read Replies (1) | Respond to of 122087
 
TRUTHSEEKER SCOOPS SEC.GOV lol-><Stuart Bockler>> Securities Exchange v. Global Datatel, Inc, et al

"4/16/2003 47 ORDER GRANTING SEC'S MOTION FOR SUMMARY JUDGMENT AND ENTERING FINAL JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AS TO DEFENDANT STUART BOCKLER granting [33-1] motion for summary judgment against defendant Stuart Bockler. Defendant shall pay disgorgement in the amount of $174,616.16, representing the proceeds he received as a result of the conduct in the complaint, together with pre-judgment interest in the amount of $7,985.16. Defendant shall pay a civil penalty in the amount of $110,000. This Court shall retain jurisdiction over this matter. The Clerk of Court shall CLOSE this case and DENY any pending motions as MOOT. (Signed by Judge Kenneth L. Ryskamp on 4/16/03) [EOD Date: 4/16/03] (at)"

US District Court for the Southern District of Florida

(West Palm Beach)

9:01cv9108

Securities Exchange v. Global Datatel, Inc, et al

This case was retrieved from the court on Monday, April 21, 2003

--------------------------------------------------------------------------------
Date Filed: 12/26/2001
Assigned To: Judge Kenneth L Ryskamp
Referred To:
Nature of suit: Securities (850)
Cause: Securities Fraud
Lead Docket: None
Other Docket: None
Jurisdiction: US Plaintiff
Class Code: AEV MEDREQ
Closed: No
Statute: 15:0077
Jury Demand:
Demand Amount: $0

Litigants Attorneys
Securities and Exchange Commission
PLAINTIFF Teresa Jacqueline Verges
[COR LD NTC]
Securities & Exchange Commission
801 Brickell Avenue Suite 1800
Miami , FL 33131
USA
305-536-4700 FTS 536-4154 305-982-6384


v.
Global Datatel, Inc
DEFENDANT
Richard Baker
DEFENDANT
Mario Habib
DEFENDANT
<<Stuart Bockler>>
DEFENDANT
Date # Proceeding Text
4/16/2003 47 ORDER GRANTING SEC'S MOTION FOR SUMMARY JUDGMENT AND ENTERING FINAL JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AS TO DEFENDANT STUART BOCKLER granting [33-1] motion for summary judgment against defendant Stuart Bockler. Defendant shall pay disgorgement in the amount of $174,616.16, representing the proceeds he received as a result of the conduct in the complaint, together with pre-judgment interest in the amount of $7,985.16. Defendant shall pay a civil penalty in the amount of $110,000. This Court shall retain jurisdiction over this matter. The Clerk of Court shall CLOSE this case and DENY any pending motions as MOOT. (Signed by Judge Kenneth L. Ryskamp on 4/16/03) [EOD Date: 4/16/03] (at)
3/21/2003 46 NOTICE of Filing a Proposed Order by Securities Exchange (at) [Entry date 03/24/03]
3/21/2003 45 PENALTY RECOMMENDATION IN SUPPORT OF ITS MOTION FOR SUMMARY JUDGMENT AND RESPONSE TO DEFENDANT STUART BOCKLER'S STATEMENT OF FINANCIAL CONDITION by Securities Exchange (at) [Entry date 03/24/03]
3/17/2003 44 Statement of Financial Condition of Stuart Bockler, by Securities Exchange (pa)
3/4/2003 -- Motion hearing re: [33-1] motion for summary judgment against defendant Stuart Bockler Motion hearing held (at) [Entry date 03/05/03]
3/4/2003 43 Minutes of Summary Judgment held before Judge Kenneth L. Ryskamp on 3/4/03; Granted affidavits to be submitted proposed order to be submitted Court Reporter Name or Tape #: Felecia Curreri (at) [Entry date 03/05/03]
2/7/2003 42 REPLY to Response to [37-1] Order to Show Cause by Securities Exchange (at) [Entry date 02/10/03]
2/7/2003 41 REPLY by Securities Exchange to [39-1] answer and exhibits (at) [Entry date 02/10/03]
2/3/2003 40 EXHIBITS IN SUPPORT to: [39-1] motion response by Stuart Bockler (at) [Entry date 02/04/03]
2/3/2003 39 ANSWER AND EXHIBITS IN SUPPORT OF HIS DEFENSE by Stuart Bockler to [33-1] motion for summary judgment against defendant Stuart Bockler (at) [Entry date 02/04/03]
2/3/2003 38 RESPONSE to [37-1] Order to Show Cause by Stuart Bockler (at) [Entry date 02/04/03]
1/22/2003 37 ORDER TO SHOW CAUSE Defendant show cause why it has not filed a response to Plaintiffs' Motion for Summary Judgment. Defendant shall have ten (10) days from the date of this Order to respond. (Signed by Judge Kenneth L. Ryskamp on 1/22/03) [EOD Date: 1/22/03] (at)
12/16/2002 36 NOTICE OF HEARING Motion hearing before Judge Kenneth L. Ryskamp set for 8:30 AM on 3/4/03 for [33-1] motion for summary judgment against defendant Stuart Bockler (Signed by Kenneth L. Ryskamp on 12/16/02) [EOD Date: 12/16/02] (at)
12/12/2002 35 EXHIBITS IN SUPPORT to: [33-1] motion for summary judgment against defendant Stuart Bockler by Securities Exchange (at) [Entry date 12/13/02]
12/12/2002 34 MEMORANDUM OF LAW by Securities Exchange in support of [33-1] motion for summary judgment against defendant Stuart (at) [Entry date 12/13/02]
12/12/2002 33 MOTION by Securities Exchange for summary judgment against defendant Stuart Bockler (at) [Entry date 12/13/02]
7/22/2002 32 NOTICE of Change of Address of attorney by Securities Exchange (at) [Entry date 07/23/02]
7/8/2002 31 NOTICE of Unavailability by Securities Exchange for dates of: 7/22/02 through 7/30/02 (at) [Entry date 07/09/02]
5/23/2002 30 ORDER GRANTING UNNOPOSED MOTION TO EXEMPT MATTER FROM MEDIATION granting [29-1] motion for an order exempting matter from mediation under local rule 16.2(C)(18) (Signed by Judge Kenneth L. Ryskamp on 5/23/02) [EOD Date: 5/23/02] (at)
5/21/2002 29 UNOPPOSED MOTION by Securities Exchange for an order exempting matter from mediation under local rule 16.2(C)(18) (at) [Entry date 05/22/02]
5/6/2002 28 NOTICE OF TRIAL set non-Jury Trial for 5/5/03 before Judge Kenneth L. Ryskamp, set Pretrial Stipulation due for 4/23/03, set Calendar Call for 1:15 p.m. on 4/30/03 before Judge Kenneth L. Ryskamp (at) [Entry date 05/07/02]
5/6/2002 27 ORDER OF REFERRAL TO MEDIATION referring case to mediation. 15 days to appoint mediator (Signed by Judge Kenneth L. Ryskamp on 5/5/02) [EOD Date: 5/7/02] (at) [Entry date 05/07/02]
5/6/2002 26 SCHEDULING ORDER setting Deadline for filing of all pretrial motions and Memoranda of law must be filed by 2/27/03; All Discovery must be completed by 1/27/03; Trial, Calendar Call and the Pretrial Stipulation due date will be set by separate notice. (Signed by Judge Kenneth L. Ryskamp on 5/5/02) [EOD Date: 5/7/02] CCAP (at) [Entry date 05/07/02]
5/6/2002 25 JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AGAINST DEFENDANT MARIO HABIB for Securities Exchange against Mario Habib, no later than 30 days from the date of this Order, pay to the United States Treasury a civil money penalty under section 20(d) of the Securities Act and Section 21(d) of the Exchange Act in the amount of $15,000. This Court shall retain jurisdiction over this matter and Defendant in order to implement and carry out the terms of all Orders and Decrees. (Signed by Judge Kenneth L. Ryskamp on 5/5/02) [EOD Date: 5/6/02] (at)
5/6/2002 24 JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AGAINST DEFENDANT RICHARD BAKER for Securities Exchange against Richard Baker, Defendant shall, no later than 30 days from the date of entry of this Order, pay to the United States Treasury a civil money penalty in amount of $25,000. This Court shall retain jurisdiction over this matter and Defendant in order to implement and carry out the terms of all Orders and Decrees that may be entered and/or to entertain any suitable application or motion for additional relief within jurisdiction of this Court, and will order other relief that this Court deems appropriate under the circumstances. (Signed by Judge Kenneth L. Ryskamp on 5/5/02) [EOD Date: 5/6/02] (at)
4/25/2002 23 NOTICE of Filing Consents of Richard Baker and Mario Habib by Securities Exchange (at) [Entry date 04/26/02]
4/25/2002 22 Scheduling Report of Scheduling Meeting by Securities Exchange (at) [Entry date 04/26/02]
4/5/2002 21 COMPLIANCE WITH LOCAL RULE 16.1 (B) by Securities Exchange (at) [Entry date 04/08/02]
2/19/2002 20 JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AGAINST DEFENDANT GLOBAL DATATEL, INC. for Securities Exchange against Global Datatel, Inc., Richard Baker, Mario Habib, Stuart Bockler ( Signed by Judge Kenneth L. Ryskamp on 2/19/02) [EOD Date: 2/20/02] (kw) [Entry date 02/20/02]
2/15/2002 19 CONSENT OF DEFENDANT GLOBAL DATATEL, INC. TO ENTRY OF JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF by Global Datatel, Inc. (kw) [Entry date 02/19/02]
2/15/2002 18 NOTICE of filing the consent of defendant Global Datatel, Inc. to entry of judgment of permanent injunction by Securities Exchange (kw) [Entry date 02/19/02]
2/4/2002 17 RETURN OF SERVICE executed for Mario Habib on 12/27/01 Answer due on 1/16/02 for Mario Habib (kw) [Entry date 02/06/02]
1/31/2002 16 NOTICE OF SETTLEMENT OFFERS filed by Securities Exchange (kw) [Entry date 02/01/02]
1/30/2002 11 Pursuant to DE# 15 in this document is returned to plaintiff (kw)
1/30/2002 10 Pursuant to DE# 15 in this document is returned to plaintiff (kw)
1/25/2002 15 ORDER granting [14-1] motion to withdraw [11-1] Statement of by Mario Habib, [10-1] Statement of by Richard Baker granting [14-2] motion to vacate [13-1] order, [12-1] order ( Signed by Judge Kenneth L. Ryskamp on 1/25/02) [EOD Date: 1/29/02] (kw) [Entry date 01/29/02]
1/24/2002 14 MOTION by Securities Exchange to withdraw [11-1] Statement of by Mario Habib, [10-1] Statement of by Richard Baker, and to vacate [13-1] order, [12-1] order (kw) [Entry date 01/29/02]
1/18/2002 13 JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AGAINST DEFENDANT MARIO HABIB ( Signed by Judge Kenneth L. Ryskamp on 1/17/02) [EOD Date: 1/23/02] (kw) [Entry date 01/23/02]
1/18/2002 12 JUDGMENT OF PERMANENT INJUNCTION AND OTHER RELIEF AGAINTS DEFENDANT RICHARD BAKER ( Signed by Judge Kenneth L. Ryskamp on 1/17/02) [EOD Date: 1/23/02] (kw) [Entry date 01/23/02]
1/16/2002 9 NOTICE of filing consents of Richard Baker and Mario Habib to entry of Judgment of Permanent Injunction by Securities Exchange (kw) [Entry date 01/22/02]
1/9/2002 8 RETURN OF SERVICE executed for Stuart Bockler on 12/27/01 Answer due on 1/16/02 for Stuart Bockler (kw) [Entry date 01/10/02]
1/9/2002 7 NOTICE of filing return of service on Stuart Bockler by Securities Exchange (kw) [Entry date 01/10/02]
12/31/2001 6 ORDER ON PRETRIAL PROCEDURES ( Signed by Judge Kenneth L. Ryskamp on 12/31/01) [EOD Date: 12/31/01] (kw)
12/27/2001 5 SUMMONS(ES) issued for Stuart Bockler (gme)
12/27/2001 4 SUMMONS(ES) issued for Mario Habib (gme)
12/27/2001 3 SUMMONS(ES) issued for Richard Baker (gme)
12/27/2001 2 SUMMONS(ES) issued for Global Datatel, Inc. (gme)
12/26/2001 1 COMPLAINT FOR INJUNCTIVE AND OTHER RELIEF filed; FEE waived; A-3; Magistrate Judge Ann E. Vitunac (gme) [Entry date 12/27/01]



To: SEC-ond-chance who wrote (83871)4/24/2003 9:37:07 PM
From: StockDung  Respond to of 122087
 
On February 28, 2001, the Commission filed a civil lawsuit against Internet Solutions For Business, Inc. (ISFB)

Internet Solutions (OTCF: ISFB)
ISFB Quote | ISFB Msg Board | ISFB LiveCharts | ISFB Chart | ISFB News | ISFB Company Info | ISFB I-Watch | ISFB Insider | ISFB Analyst Recs | ISFB Top Holders


« ISFB Message list | Reply to msg. | Post new msg. « Older | Newer »
By: EnforcementSEC
01 Mar 2001, 11:01 AM EST Msg. 709 of 740
Jump to msg. #
The SEC Division of Enforcement would like to hear from individuals who have communicated directly with ISFB and Lawrence Shaw.

On February 28, 2001, the Commission filed a civil lawsuit against Internet Solutions For Business, Inc. (ISFB) and its founder and CEO, Lawrence Shaw. The SEC&#146;s action pertains to the allegedly fraudulent promotional activities by ISFB, a publicly traded Internet company located in Coventry, England.

From March 1999 until at least October 2000, ISFB held itself out as a sophisticated, high-tech Internet company with cutting edge new products and profitable business relationships with recognizable &#147;blue chip&#148; companies. ISFB hyped these products and relationships on its website, in press releases and through reports it paid to have published. All the promotional statements contained on ISFB&#146;s website and in its releases, and which were repeated in the published reports, were authorized by Shaw.

The SEC alleges that ISFB&#146;s promotional statements were false and mislea